Suppr超能文献

糖尿病、肥胖症和血脂异常对慢性肝病患者肝细胞癌风险的影响。

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.

机构信息

Department of Family Medicine, Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine, Cheonan, Korea.

Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2022 Oct;28(4):773-789. doi: 10.3350/cmh.2021.0383. Epub 2022 Aug 8.

Abstract

Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.

摘要

尽管代谢紊乱的患病率不断增加,但代谢因素对慢性肝病(CLD)患者肝细胞癌(HCC)发展的潜在影响尚未得到充分认识。代谢因素要被确定为 CLD 患者(如乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染)的 HCC 危险因素,代谢因素的致癌机制与 CLD 本身之间应该存在强烈的协同相互作用。这篇综述旨在全面总结已发表的关于代谢因素(如糖尿病(DM)、肥胖和血脂)与 CLD 患者 HCC 风险之间关系的研究数据。DM 始终会增加 CLD 患者 HCC 的风险。当与 DM 相关时,HCV 和非酒精性脂肪性肝病(NAFLD)似乎 HCC 的风险最高,其次是酒精性肝病(ALD)和 HBV。肥胖可能会增加 HCC 的风险。在 CLD 中,ALD 的证据相对一致且明确,而在其他 CLD 中,包括 HBV、HCV 和 NAFLD,明确证据有限。在 CLD 患者中,总胆固醇、潜在的低密度脂蛋白胆固醇和甘油三酯似乎与 HCC 呈强负相关。尽管观察性研究有证据,但他汀类药物在随机对照试验中对预防 HCC 没有影响。他汀类药物是否对 HCC 有预防作用尚不清楚。更好地了解和管理代谢因素可能有助于降低 CLD 患者 HCC 的风险。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验